● Emeryville, California-based Estrella Immunopharma develops engineered T-cell therapies for blood cancers, led by EB103, a CD19-directed candidate built on its ARTEMIS T-cell receptor platform.
The ticker EAPH (OTC:EAPH) has indeed gone quiet, and in more ways than a flatTrading sessionsuggests. The symbol once belonged to Easton Pharmaceuticals Inc., a Toronto-based company that has since rebranded to Parallel Industries Inc. and, by available accounts, no longer conducts significant operations. …
eHouse Global (OTC:EHOS) is a reminder that not every ticker on a screener belongs to a living, reporting company. The stock trades at a fraction of a cent, and the entity behind it stopped filing with the U.S. Securities and Exchange Commission roughly a …
Elite Pharmaceuticals has quietly become one of the more striking turnaround stories in the generic-drug business, yet its shares have drifted lower even as the company posts record numbers. The pullback in Elite Pharmaceuticals, Inc (OTCQB: ELTP) stock stands in sharp contrast to a …
Elicio Therapeutics has spent 2026 navigating one of the hardest stretches a clinical-stage biotech can face: a lead trial that missed its primary goal, followed by the difficult work of resetting its strategy. Against that backdrop, a single-day slide in Elicio Therapeutics, Inc (NASDAQ: …
A commercial-stage medical-device maker reshaping itself around a single regulatory catalyst, Elutia Inc. (NASDAQ: ELUT) has become a study in transition. The stock hovers near $0.80 with a market capitalization around $35 million after a steep year-long decline, and September finds investors weighing a …
Few 2022-era spin-offs have travelled a rockier road than Embecta Corp (NASDAQ: EMBC), the diabetes-care company carved out of Becton, Dickinson. After a punishing 2026, another single-session slide has again put the maker of pen needles and syringes in focus. The move fits a …
Emergent Health Corp (OTC:EMGE) is the kind of ticker that surfaces on lists of the market's lowest-priced shares, trading at a fraction of a cent with no movement in the last closing session. The harder truth is that the company has left almost no …
● The recent daily decline in CTXR shares has no single identifiable public catalyst and is characteristic of a low-priced, thinly capitalized stock.
A pullback of nearly 7% in a single session has drawn eyes to Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR), a newly public, Singapore-based biomedical micro-cap trading around $2.91. For a company this small, sharp swings are routine, and the recent decline does not trace …